Related Articles
Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice
Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells
Systemic or topical application of plasminogen activator inhibitor with extended half-life (VLHL PAI-1) reduces bleeding time and total blood loss
Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review).
Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure